ADXS Short Information, Advaxis Inc.

Twenty Trading Day Totals
Total Shorted Volume	13,698,318
Total Actual Volume	69,998,949

Averages
Average Short Volume	684,916
Average Short Percentage	49.64%

Is there a ADXS Short Squeeze or Breakout about to happen?

See the ADXS Short Analysis for free Sign up or Login

Stock Date	Open Price	Close Price	High	Low	Total Volume	Short Volume	Short Percentage
2021-12-22	0.29	0.24	0.2902	0.2356	11,640,473	1,546,604	57.5515
2021-12-21	0.3033	0.2943	0.3033	0.287	3,165,617	680,882	50.4197
2021-12-20	0.32	0.2962	0.32	0.2746	3,752,751	784,883	44.2700
2021-12-17	0.3204	0.325	0.328	0.305	2,379,154	299,470	43.8221
2021-12-15	0.3	0.3174	0.3245	0.293	1,714,019	458,576	60.4600
2021-12-14	0.3126	0.309	0.3299	0.3	2,765,718	845,020	77.0690
2021-12-13	0.3159	0.3126	0.33	0.3045	1,798,014	352,127	46.2231
2021-12-10	0.3718	0.325	0.377	0.32	3,015,216	892,258	72.9052
2021-12-09	0.3692	0.3478	0.382	0.347	2,360,508	360,425	39.1726
2021-12-08	0.343	0.36	0.366	0.3398	1,672,367	88,699	17.5208
2021-12-07	0.3538	0.3544	0.3799	0.35	2,844,696	207,966	20.1348
2021-12-06	0.3134	0.3445	0.348	0.3013	2,738,762	456,561	37.9402
2021-12-01	0.37	0.3444	0.3725	0.3302	3,256,281	796,957	49.6899
2021-11-30	0.4	0.37	0.41	0.365	3,299,557	670,515	49.0342
2021-11-29	0.3902	0.4002	0.42	0.3622	8,359,562	1,836,043	58.2527
2021-11-26	0.3763	0.3847	0.3897	0.365	1,656,652	342,388	60.1244
2021-11-24	0.3665	0.4017	0.4199	0.36	5,426,460	1,499,010	59.1119
2021-11-23	0.3796	0.3621	0.3796	0.3501	1,868,892	293,011	42.5467
2021-11-22	0.3807	0.368	0.3886	0.3508	3,302,961	613,494	47.6001
2021-11-19	0.379	0.3772	0.3902	0.37	2,981,289	673,429	58.9473

Stock Information

Advaxis Inc. Company Name:

ADXS Stock Symbol:

NASDAQ Market:

Advaxis Inc. Website:

ADXS Short Information, Advaxis Inc.

Get ADXS Alerts

News, Short Squeeze, Breakout and More Instantly...

ADXS - Advaxis Updates on the Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate Cancer

Evaluation completed of first dose level in investigator-sponsored study in biochemically recurrent prostate cancer Enrollment initiated for second dose level MONMOUTH JUNCTION, N.J., June 29, 2022 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnol...
ADXS - Advaxis Reports Second Quarter Ended April 30, 2022 Financial Results and Provides a Business Update

Announced Publication of ADXS-PSA Data in The Oncologist Presented Updated Clinical and Immunogenicity Data from Ongoing Phase 1/2 Trial of ADXS-503 in NSCLC at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting Presented study design of Phase 1 investiga...
ADXS - Advaxis, Inc. Announces 1-for-80 Reverse Stock Split

MONMOUTH JUNCTION, N.J., June 03, 2022 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that it has filed a Certificate of Amendme...